Autonomix Medical, Inc. (AMIX)
| Market Cap | 3.84M -22.1% |
| Revenue (ttm) | n/a |
| Net Income | -17.24M |
| EPS | -3.40 |
| Shares Out | 11.41M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,518,661 |
| Open | 0.2840 |
| Previous Close | 0.2836 |
| Day's Range | 0.2701 - 0.3990 |
| 52-Week Range | 0.2002 - 2.6400 |
| Beta | -1.80 |
| Analysts | Buy |
| Price Target | 2.00 (+494.35%) |
| Earnings Date | May 29, 2026 |
About AMIX
Autonomix Medical, Inc., a development stage medical device company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. The company’s technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. It develops technology for patients with pancreatic cancer and addresses indications for chronic pain management, hypertension, cardiovascular, and other nerve-related disorders. Autonomix Medical, Inc. was incorporated in... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for AMIX stock is "Buy." The 12-month stock price target is $2.0, which is an increase of 494.35% from the latest price.
News
Autonomix granted U.S. patent for transvascular monitoring, treatment systems
Autonomix (AMIX) announced the United States Patent and Trademark Office has issued U.S. Patent No. 12,544,131. The newly granted patent covers catheter-based transvascular tools and systems designed ...
Autonomix Medical, Inc. Granted U.S. Patent for Transvascular Monitoring and Treatment Systems with Real-Time Procedural Validation
Technology unlocks minimally invasive transvascular access to nerve targets and tissues through and beyond the lumen wall
Autonomix Medical Announces Abstract Acceptances at EuroPCR 2026 Showcasing Long-Term Data in Pancreatic Cancer Pain Mitigation
THE WOODLANDS, TX, May 18, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted trea...
Autonomix Medical Announces Abstract Acceptance at Digestive Disease Week 2026 Showcasing Long-Term Data in Pancreatic Cancer Pain Mitigation
THE WOODLANDS, TX, April 29, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted tr...
Autonomix Medical to Present Long-Term Pain Mitigation Data in Pancreatic Cancer at ECIO 2026
THE WOODLANDS, TX, April 22, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted tr...
Autonomix Medical Selected for Featured Abstract and Podium Presentation of Long-Term Pain Mitigation in Pancreatic Cancer at SIR 2026
THE WOODLANDS, TX, April 08, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted tr...
Autonomix Medical to Present at LSI USA '26
THE WOODLANDS, TX, March 11, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted tr...
Autonomix Medical Selected for Best Innovation Competition at CRT 2026
THE WOODLANDS, TX, March 05, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted tr...
Autonomix to present clinical study on Nerve Neurolysis at CRT 2026
Autonomix (AMIX) Medical announced that Nikola Cesarovic, PhD, will present clinical feasibility and outcome data at the Cardiovascular Research Technologies, CRT, 2026 Meeting, happening March 7-10, ...
Autonomix Medical Selected as Top Abstract at CRT 2026 and Selected for Podium Presentation of Clinical Feasibility and Outcomes of Novel Technique for Transvascular Peripheral RF Nerve Neurolysis
THE WOODLANDS, TX, March 04, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted tr...
Autonomix Medical Announces Release of New CEO Corner Segment Highlighting Publication Strategy and Scientific Validation
CEO, Brad Hauser, discusses building clinical credibility through rigorous science and peer-reviewed engagement THE WOODLANDS, TX, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AM...
Autonomix selected to present new long-term pain mitigation data at SSO 2026
Autonomix (AMIX) Medical announced that Clarke Wilkirson, PhD, Clinical Development Engineer II, will present new long-term clinical data at the Society of Surgical Oncology, SSO, 2026 Annual Meeting,...
Autonomix Medical Selected to Present New Long-Term Pain Mitigation Data in Pancreatic Cancer at SSO 2026 Annual Meeting in Podium Presentation
THE WOODLANDS, TX, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted tre...
Autonomix price target lowered to $2 from $5 at Maxim
Maxim lowered the firm’s price target on Autonomix (AMIX) to $2 from $5 and keeps a Buy rating on the shares. The company’s Q3 results were slightly better than expected,…
Autonomix announces final clinical data on pain mitigation in pancreatic cancer
Autonomix (AMIX) Medical announced that final clinical data evaluating its transvascular radiofrequency ablation approach for pain mitigation in pancreatic adenocarcinoma will be presented at the Soci...
Autonomix showcases PoC study clinical data at 2026 ASCO Symposium
Autonomix (AMIX) Medical announced new subgroup clinical data from its PoC study presented at the 2026 ASCO Gastrointestinal Cancers Symposium demonstrating rapid, durable and meaningful pain relief i...
Autonomix Showcases Compelling PoC Study Clinical Data Showing Rapid and Durable Pain Relief Across All Disease Stages of Pancreatic Cancer at the 2026 ASCO Gastrointestinal (GI) Cancers Symposium
New subgroup analysis shows consistent, clinically meaningful pain reduction observed from Stage 2 through Stage 4 disease, including late-stage patients with otherwise limited treatment options
Autonomix granted European patent on nerve-targeted therapies technology
Autonomix (AMIX) Medical announced the European Patent Office has granted Patent No. EP4230133, titled, “Controlled and Precise Treatment of Cardiac Tissues.” The newly granted ‘133 patent covers syst...
Autonomix Medical, Inc. (NASDAQ: AMIX) Highlights Expanding IP Portfolio and Multi-Indication Platform Strategy in Virtual Investor CEO Connect Segment
Access the segment here
Autonomix Medical, Inc. Announces Abstract Selected for Poster Presentation at the 2026 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium
THE WOODLANDS, TX, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted tre...
Autonomix files to sell 13.5M shares of common stock for holders
This offering relates to the resale by the selling stockholder of up to an aggregate of 9,003,332 shares of Autonomix (AMIX) common stock issuable upon exercise of certain outstanding Series…
Autonomix Medical, Inc. (NASDAQ: AMIX) Announces Release of the Next CEO Corner Segment Highlighting Continued Execution and Strategic Growth
THE WOODLANDS, TX, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted tre...
Autonomix prices 4.5M shares at $1.11 in private placement
Autonomix (AMIX) Medical entered into a securities purchase agreement with a single institutional investor to purchase 4,501,666 shares of common stock and together with unregistered Series C warrants...
Autonomix reports results from exploratory subgroup analysis on PoC study
Autonomix (AMIX) Medical announced results from a post-hoc exploratory subgroup analysis of its previously reported first-in-human proof-of-concept study, PoC 1, evaluating the safety and effectivenes...
Autonomix Medical, Inc. Featured in Two Innovation in Interventional Cardiology Podium Presentations at the Transcatheter Cardiovascular Therapeutics® (TCT®) Annual Scientific Conference
THE WOODLANDS, TX, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted tre...